Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma

Trial Profile

Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Naxitamab (Primary) ; Irinotecan; Sargramostim; Temozolomide
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jan 2019 Planned number of patients changed from 20 to 36.
    • 03 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
    • 03 Jan 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top